BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ABT-450: Additional Phase II data

Additional data from the ongoing, double-blind, dose-ranging Phase II M11-602 trial in 35 treatment-naïve patients with HCV genotype 1 infection showed that a significantly greater proportion of patients receiving once-daily ABT-450 plus Norvir ritonavir and standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) (n=24) achieved a complete EVR defined as HCV RNA...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >